ICR welcomes recommendation of talazoparib for advanced breast cancer 19 Jan 2024 The Institute of Cancer Research, London, strongly welcomes the news that talazoparib (trade name Talzenna) has been recommended by NICE for the treatment of advanced breast cancer. Find out more Show/Hide
Existing cancer drugs have potential to benefit thousands more patients 31 Jul 2023 Existing targeted cancer drugs could help even more patients, including some with the most common type of breast cancer, scientists have discovered. Find out more Show/Hide
Meet our scientists at upcoming industry collaboration events 22 Feb 2023 Upcoming events will give industry experts the chance to hear from some of our leading researchers about opportunities to work with them. Find out more Show/Hide
AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment 04 Apr 2022
ESMO Virtual Plenary 2022: Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation 16 Mar 2022